Cytek Biosciences, Inc. (CTKB)Healthcare | Medical Devices | Fremont, United States | NasdaqGS
5.43 USD
+0.03
(0.556%)
⇧
(Oct. 15, 2026, 11:08 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:46 a.m. EDT
The long-term investment case is fundamentally broken. The company has endured four consecutive years of negative annual returns, culminating in an 82% cumulative decline over the last four years. This is not a temporary setback; it is a structural implosion where the market has repeatedly rejected the business model, driving the price from $21.61 to under $4. Fundamentals confirm the distress: the company is burning cash with negative operating margins of nearly 30%, negative free cash flow, and a return on equity of -23%. While the balance sheet shows low debt relative to equity, the inability to generate profit or cash flow renders the capital inefficient. The stock trades at a forward P/E of 77x based on tiny expected earnings, reflecting extreme uncertainty rather than value. With no dividend to provide income and a trajectory that suggests the core business is failing to gain traction, this is a clear 'avoid' situation. The short-term outlook remains bleak due to this deepening fundamental rot, though the low float and high short interest (5%) suggest potential for volatility if a catalyst emerges. However, without a proven turnaround in revenue growth or profitability, the risk of permanent capital loss outweighs any speculative upside. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.062606 |
| AutoETS | 0.062628 |
| AutoTheta | 0.066333 |
| MSTL | 0.068052 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 5.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.038 |
| Excess Kurtosis | 0.52 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.219 |
| Revenue per Share | 1.609 |
| Market Cap | 705,159,168 |
| Forward P/E | 77.50 |
| Beta | 1.16 |
| Profit Margins | -38.98% |
| Website | https://cytekbio.com |
As of Oct. 10, 2026, 4:46 a.m. EDT: Speculator positioning is extremely thin and non-directional. Open interest is negligible across all expirations, with no significant concentration at strikes above or below the current price. Implied volatility is low, indicating a lack of speculative fear or greed. The market appears to have effectively ignored this name, resulting in a flat, uninformative options landscape.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.34203982 |
| Address1 | 47,215 Lakeview Blvd |
| All Time High | 28.7 |
| All Time Low | 2.37 |
| Ask | 6.87 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 1,742,740 |
| Average Daily Volume3 Month | 1,114,651 |
| Average Volume | 1,114,651 |
| Average Volume10Days | 1,742,740 |
| Beta | 1.16 |
| Bid | 3.93 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 2.477 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.425 |
| Current Ratio | 4.481 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 5.455 |
| Day Low | 5.3 |
| Debt To Equity | 8.219 |
| Display Name | Cytek Biosciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -39,761,000 |
| Ebitda Margins | -0.19235 |
| Enterprise To Ebitda | -11.713 |
| Enterprise To Revenue | 2.253 |
| Enterprise Value | 465,715,648 |
| Eps Current Year | -0.12 |
| Eps Forward | 0.07 |
| Eps Trailing Twelve Months | -0.62 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.0151 |
| Fifty Day Average Change | 0.4099002 |
| Fifty Day Average Change Percent | 0.081733204 |
| Fifty Two Week Change Percent | 34.203983 |
| Fifty Two Week High | 6.21 |
| Fifty Two Week High Change | -0.78499985 |
| Fifty Two Week High Change Percent | -0.126409 |
| Fifty Two Week Low | 3.31 |
| Fifty Two Week Low Change | 2.1150002 |
| Fifty Two Week Low Change Percent | 0.6389729 |
| Fifty Two Week Range | 3.31 - 6.21 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,047,000,000 |
| Float Shares | 102,941,537 |
| Forward Eps | 0.07 |
| Forward P E | 77.5 |
| Free Cashflow | 9,295,375 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 682 |
| Fullday Change | 0.03000021 |
| Fullday Change Percent | 0.5560743 |
| Fullday Price | 5.425 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.51875 |
| Gross Profits | 107,230,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08472 |
| Held Percent Institutions | 0.62969 |
| Implied Shares Outstanding | 129,983,253 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-23 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. |
| Long Name | Cytek Biosciences, Inc. |
| Market | us_market |
| Market Cap | 705,159,168 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_422081633 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -80,578,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 738,304,877 |
| Number Of Analyst Opinions | 4 |
| Open | 5.36 |
| Operating Cashflow | -6,038,000 |
| Operating Margins | -0.29497 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 877 922 9835 |
| Previous Close | 5.395 |
| Price Eps Current Year | -45.208336 |
| Price Hint | 2 |
| Price To Book | 2.1901495 |
| Price To Sales Trailing12 Months | 3.411362 |
| Profit Margins | -0.38981 |
| Quick Ratio | 3.715 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.25 |
| Region | US |
| Regular Market Change | 0.03000021 |
| Regular Market Change Percent | 0.5560743 |
| Regular Market Day High | 5.455 |
| Regular Market Day Low | 5.3 |
| Regular Market Day Range | 5.3 - 5.455 |
| Regular Market Open | 5.36 |
| Regular Market Previous Close | 5.395 |
| Regular Market Price | 5.425 |
| Regular Market Time | 1,792,076,928 |
| Regular Market Volume | 230,501 |
| Return On Assets | -0.06308 |
| Return On Equity | -0.23038 |
| Revenue Growth | 0.056 |
| Revenue Per Share | 1.609 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 129,983,253 |
| Shares Percent Shares Out | 0.0401 |
| Shares Short | 5,215,595 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,931,028 |
| Short Name | Cytek Biosciences, Inc. |
| Short Percent Of Float | 0.0508 |
| Short Ratio | 4.0 |
| Source Interval | 15 |
| State | CA |
| Symbol | CTKB |
| Target High Price | 7.5 |
| Target Low Price | 4.75 |
| Target Mean Price | 5.5625 |
| Target Median Price | 5.0 |
| Total Cash | 262,004,000 |
| Total Cash Per Share | 2.016 |
| Total Debt | 26,460,000 |
| Total Revenue | 206,708,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.632975 |
| Two Hundred Day Average Change | 0.7920251 |
| Two Hundred Day Average Change Percent | 0.17095388 |
| Type Disp | Equity |
| Volume | 230,501 |
| Website | https://cytekbio.com |
| Zip | 94,538-6407 |